MYNX CONTROL Vascular Closure Device

Name: Cordis
Price range: $

Extravascular closure designed for procedural control and patient comfort.

The MYNX CONTROL^® Vascular Closure Device (VCD) provides reliable arterial access site closure using a bioabsorbable PEG sealant and GRIP TECHNOLOGY^®. The system is designed to deliver controlled, extravascular sealing supporting rapid hemostasis and improved patient recovery.

Request Additional Information MYNX CONTROL VCD Brochure

Closing the Femoral Access Site Efficiently and Safely

Femoral access procedures require reliable vascular closure that balances procedural efficiency, patient comfort, and safety. Traditional closure techniques may involve longer recovery times, intravascular implants, or inconsistent hemostasis.

MYNX CONTROL VCD is designed to provide controlled extravascular sealing without leaving anything permanent inside the artery.

A Controlled Approach to Vascular Closure

MYNX CONTROL VCD combines a simple delivery system with GRIP TECHNOLOGY to provide secure extravascular closure.

The device uses a bioabsorbable PEG sealant that expands within the tissue tract to seal the arteriotomy while remaining outside the vessel lumen.

Two-button deployment system
Sheath catch for precise positioning
PEG sealant technology
Extravascular closure approach

How MYNX CONTROL VCD Achieves Closure

MYNX CONTROL VCD Step-by-Step

This animated overview highlights the key features and mechanism of the MYNX CONTROL Vascular Closure Device, illustrating how the system is designed to support secure and efficient femoral artery closure. Watch to better understand device functionality and procedural benefits in a clear, visual format.

MYNX CONTROL VCD Actual Physician Case

This physician procedure video demonstrates the MYNX CONTROL Vascular Closure Device, highlighting key techniques for effective and reliable femoral artery closure. Gain practical insights to support consistent outcomes and streamline your post-procedural workflow.

GRIP TECHNOLOGY Active Sealing

MYNX CONTROL VCD uses GRIP TECHNOLOGY, a combination of mechanical positioning and PEG sealant expansion that delivers reliable extravascular closure. The hydrophilic polyethylene glycol sealant expands within the tissue tract and forms a seal that mimics the structure of a natural fibrin clot.

Grip Tip
Helps secure positioning at the arteriotomy.

PEG Sealant
Expands and interlocks within the tissue tract.

Extravascular Closure
Leaves nothing permanent behind.

MYNX CONTROL VCD

MYNX Portfolio of Vascular Closure Devices (VCP) Clinical Evidence

Proven Effective in Real-World Use

A retrospective, single-center study of 432 consecutive patients undergoing elective and diagnostic coronary angiography found MYNX® Vascular Closure Portfolio (VCP) to be effective and safe*

*Hutchings D, Hayat A, Karunakaran A, Malik N. Success, safety, and efficacy of the Mynx femoral closure device in a real-world cohort: single-center experience. J Invasive Cardiol. 2016 Mar;28(3): 104-108.

Reduced Incident Rate

In a blinded, randomized clinical study, there was a significantly reduced incident rate for MYNX VCP as compared to Angio-Seal VCD.*

*Fargen KM, Hoh BL, Mocco J. A prospective randomized single-blind trial of patient comfort following vessel closure: extravascular synthetic sealant closure provides less pain than a self-tightening suture vascular compression device. J Neurointerv Surg. 2011 Sep; 3(3): 219-223.

Patient Comfort

Clinical studies indicate MYNX VCP technology supports faster hemostasis and earlier patient ambulation as compared to traditional methods.*

Product Characteristics

Scroll, sort or search for the particular MYNX CONTROL Vascular Closure Device's part number of interest.

SKU	Product Description	Sheath Compatibility (F)	Qty/box	Where Used/Indication
MX6760	MYNX CONTROL Vascular Closure Device 6/7F	6/7	10	Femoral artery
MX5060	MYNX CONTROL Vascular Closure Device 5F	5	10	Femoral artery

Resources

MYNX CONTROL VCD Step-by-Step Poster

References

Clinical Articles

_{The MYNXGRIP™ Vascular Closure Device Hoang Minh Thai, MD, FACC, FSCAI, and Barry S. Weinstock, MD. Endovascular Today. April 2012.}

_{Successful Reduction of Surgeries Secondary to Arterial Access Site Complications A Retrospective Review at a Single-Center with an Extravascular Closure Device. Noor S, Meyers S, Curl R. Vascular and Endovascular Surgery. May 2010;44(5):345-9.}

_{A Prospective Randomized Single-blind trial of Patient Comfort Following Vessel Closure Extravascular Synthetic Sealant Closure Provides Less Pain than a Self-tightening Suture Vascular Compression Device. Fargen KM, Hoh BL, Mocco J. J Neurointerv Surg. 2011;3(3):219-23}

_{Mynx Vascular Closure Device Early Ambulation Study Vikranth R. Gongidi, DO; Ahsan Jafir, DO; and Vijay Verma, MD, FACC, FSCAI. Endovascular Today. October 2013}

_{Occurrence of angiographic femoral artery complications after vascular closure with Mynx and AngioSeal Fargen KM, Velat GJ, Lawson MF, et al. Journal of Neurolnterventional Surgery. 2013;5(2):161-4}

_{Use of Vascular Closure Device After Access of Common Femoral Artery Through an Existing Stent George JC. Vascular Disease Management. 2012;9(5):E68-E70.}

_{Two Years of Extravascular Closure With the MYNX CONTROL™ Vascular Closure Device The Baptist Memorial Hospital experience revisited. David Wolford, MD, FACC. Endovascular Today. August 2010.}

_{Why Extravascular Closure? The Baptist Memorial Hospital Experience with the Mynx Vascular Closure Device David Wolford, MD, FACC. Endovascular Today. August 2009.}

_{The Safety and Efficacy of an Extravascular, Water-Soluble Sealant for Vascular Closure Initial Clinical Results for Mynx. D. Scheinert MD et al. Catheterization and Cardiovascular Interventions. November 2007.}

Footnotes

^{1. Scheinert D, Sievert H, Turco MA, et al. The safety and efficacy of an extravascular, water‐soluble sealant for vascular closure: Initial clinical results for Mynx. Cathet Cardiovasc Intervent. 2007 Oct;70:627-633.}

^{2 MYNX CONTROL Vascular Closure Device Instructions for Use.}

^{3 Pruski MJ Jr, Blachut AM, Konkolewska M, et al. MynxGrip for closure of antegrade puncture after peripheral interventions with same-day discharge. Vasc Endovasc Surg. 2017 Feb;51(2):67-71.}

^{4 Baker NC, Escarcega RO, Lipinski MJ, et al. Active versus passive anchoring vascular closure devices following percutaneous coronary intervention: a safety and efficacy comparative analysis. J Interv Cardiol. 2016 Feb; 29(1): 108-112.}

^{5 Hutchings D, Hayat A, Karunakaran A, Malik N. Success, safety, and efficacy of the Mynx femoral closure device in a real-world cohort: single-center experience. J Invasive Cardiol. 2016 Mar;28(3):104-108.}

^{6 Noor S, Meyers S, Curl R. Successful reduction of surgeries secondary to arterial access site complications: a retrospective review at a single center with an extravascular closure device. Vasc Endovascular Surg. 2010 Jul;44(5):345-349.}

^{7 Fargen KM, Hoh BL, Mocco J. A prospective randomized single-blind trial of patient comfort following vessel closure: extravascular synthetic sealant closure provides less pain than a self-tightening suture vascular compression device. J NeuroInterv Surg. 2011 Sep; 3(3): 219-223.}

^{† Confirm vessel size is ≥ 5 mm}

^{‡Time to discharge eligibility as compared to manual compression. MATRIX Clinical Trial (IDE# G030182)}

IFU

Please refer to the Instructions for Use for complete information, including indications, precautions, warnings, and potential adverse events.

Customer Service and Ordering Information

In the United States, email us your question or order, or call us at 800.327.7714.